BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 29-Jan-2017

(Q2 Un-audited): Consolidated EPS was Tk. 3.58 for October-December, 2016 as against Tk. 3.21 for October-December, 2015; Consolidated EPS was Tk. 7.11 for July-December, 2016 as against Tk. 6.10 for July-December, 2015. Consolidated NOCFPS was Tk. 8.54 for July-December, 2016 as against Tk. 8.93 for July-December, 2015. Consolidated NAV per share was Tk. 63.00 as of December 31, 2016 and Tk. 59.13 as of June 30, 2016.

SQURPHARMA 14-Nov-2016

(Q1 Un-audited): Consolidated EPS was Tk. 3.89 for July-September, 2016 as against Tk. 3.18 for July-September, 2015; Consolidated NOCFPS was Tk. 5.67 for July-September, 2016 as against Tk. 4.03 for July-September, 2015. Consolidated NAV per share was Tk. 69.17 as of September 30, 2016 and Tk. 65.04 as of June 30, 2016.

SQURPHARMA 17-Oct-2016

(continuation news of SQURPHARMA): The Company has also reported EPS of Tk. 14.80, NAV per share of Tk. 57.08 and NOCFPS of Tk. 15.88 for the 15 months period ended on June 30, 2016 which was Tk. 10.46, Tk. 44.95 and Tk. 12.21 respectively for 15 months period from Jan 2014 to March 2015. (end)

SQURPHARMA 31-Jan-2016

(Q3 Un-audited): Consolidated EPS was Tk. 3.39 for October-December, 2015 as against Tk. 2.45 for October-December, 2014; Consolidated EPS was Tk. 9.48 for April-December, 2015 as against Tk. 6.77 for April-December, 2014. Consolidated NOCFPS was Tk. 12.59 for April-December, 2015 as against Tk. 7.75 for April-December, 2014. Consolidated NAV per share was Tk. 56.86 as of December 31, 2015 and Tk. 49.86 as of March 31, 2015.

SQURPHARMA 28-Oct-2015

(Q2 Un-audited): Consolidated EPS was Tk. 3.18 for July-September, 2015 as against Tk. 2.09 for July-September, 2014; Consolidated EPS was Tk. 6.09 for April-September, 2015 as against Tk. 4.32 for April-September, 2014. Consolidated NOCFPS was Tk. 6.87 for April-September, 2015 as against Tk. 3.94 for April-September, 2014. Consolidated NAV per share was Tk. 53.37 as of September 30, 2015 and Tk. 49.86 as of March 31, 2015.

SQURPHARMA 16-Aug-2015

(Q1 Un-audited): Consolidated EPS for April-June, 2015 was Tk. 3.28 as against Tk. 2.51 for April-June, 2014; Consolidated NOCFPS was Tk. 3.11 for April-June, 2015 as against Tk. 1.76 for April-June, 2014. Consolidated NAV per share was Tk. 59.38 as of June 30, 2015 and Tk. 56.09 as of March 31, 2015.

SQURPHARMA 21-Jul-2015

(Continuation news of SQURPHARMA): The Company has also reported consolidated NAV of Tk. 31,093.30 million, consolidated EPS of Tk. 10.80 and consolidated NOCFPS of Tk. 11.68 for the year ended on March 31, 2015. (end)

SQURPHARMA 01-Feb-2015

(Q3 Un-audited): Consolidated profit after tax (excluding non controlling interest) from Oct'14 to Dec'14 was Tk. 1,527.92 million with consolidated EPS of Tk. 2.76 as against Tk. 1,508.31 million and Tk. 2.72 respectively for the same period of the previous year. Whereas consolidated profit after tax from Apr'14 to Dec'14 was Tk. 4,220.59 million with consolidated EPS of Tk. 7.61 as against Tk. 4,104.82 million and Tk. 7.41 respectively for the same period of the previous year.

SQURPHARMA 02-Nov-2014

(H/Y): As per un-audited half yearly accounts as on 30.09.2014 (April'14 to Sep'14), the Company has reported consolidated net profit after tax (excluding non-controlling interests) of Tk. 2,692.67 million with consolidated EPS of Tk. 4.86 as against Tk. 2,515.49 million and Tk. 4.54 respectively for the same period of the previous year. Whereas consolidated net profit after tax (excluding non-controlling interests) was Tk. 1,303.78 million with consolidated EPS of Tk. 2.35 for the period of 3 months (July'14 to Sep'14) ended on 30.09.2014 as against Tk. 1,183.65 million and Tk. 2.14 respectively for the same period of the previous year.

SQURPHARMA 20-Jul-2014

The Board of Directors has recommended 30% cash dividend and 15% stock dividend for the year ended on March 31, 2014. Date of AGM: 25.09.2014, Time: 10:00 AM, Venue: Factory premises, Kaliakoir, Gazipur. Record Date: 26.08.2014. The Company has also reported NAV of Tk. 22,277.52 million, EPS of Tk. 8.36 and NOCFPS of Tk. 12.90 for the year ended on March 31, 2014.

Previous Next page